

Re: Phi Med Europe: NerveCheck Quotation

Hao Chen <chenhao@biofourmis.com>

Thu 16 Jun 2022 11:26 AM

To: Chris Wilson <chris.wilson@biofourmis.com>;Sandi Wibowo <sandi@biofourmis.com>

Thanks, Chris.

This is a well-known device. Their paper publication looks good (e.g. IF > 5.0); But let's take another 1 week to see if there's any other device available & price-feasible. Thanks!

"METHODS: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain.

RESULTS: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. **The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower ($P \leq 0.0001$) in diabetic patients with DPN compared to patients without DPN."**

1

Cite

Share

NerveCheck: An inexpensive quantitative sensory testing device for patients with diabetic neuropathy.

SCI升级版 医学3区

SCI基础版 医学2区

SCI Q1

SCIIF 5.602

CUG 医学T3

XJU 三区

Ponirakis G, Odriozola MN, Odriozola S, Petropoulos IN, Azmi S, Fadavi H, Alam U, Asghar O, Marshall A, Miro A, Kheyami A, Al-Ahmar A, Odriozola MB, Odriozola A, Malik RA. Diabetes Res Clin Pract. 2016 Mar;113:101-7. doi: 10.1016/j.diabres.2015.12.023 (e). Epub 2016 Jan 14. PMID: 26830855 (e) Free PMC article. Clinical Trial. AIMS: Sensory neuropathy is central to the development of painful neuropathy, and foot ulceration in patients with diabetes. Currently, available QST devices take considerable time to perform and are expensive. NerveCheck is the first ...

Q1

IF: 5.602

Cited by: 13

Sci-Hub Link

PDF(Full Text)

Citation

Collect

2

Cite

Share

NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes.

SCI升级版 医学2区

SCI基础版 医学2区

SCI Q1

SCIIF 6.118

CUG 医学T3

XJU 二区

Ponirakis G, Odriozola MN, Odriozola S, Petropoulos IN, Azmi S, Ferdousi M, Fadavi H, Alam U, Marshall A, Jeziorska M, Miro A, Kheyami A, Tavakoli M, Al-Ahmar A, Odriozola MB, Odriozola A, Malik RA. Diabetes Technol Ther. 2016 Dec;18(12):800-805. doi: 10.1089/dia.2016.0279 (e). Epub 2016 Dec 6. PMID: 27922760 (e) Free PMC article. Clinical Trial. BACKGROUND: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of ...

Q1

IF: 6.118

Cited by: 6

Sci-Hub Link

PDF(Full Text)

Citation

Collect

https://outlook.office.com/mail/inbox/id/AAQkAGVIM2IwOTI3LWJjOTEtNDU3Zi04Y2Q3LTkzZGY3NWMwYTkxZgAQAFUO5EF0N9FiQo%2BTQVi1I%3D

1/3

From: Chris Wilson <chris.wilson@biofourmis.com>
Sent: Thursday, 16 June 2022 10:16 am
To: Sandi Wibowo <sandi@biofourmis.com>; Hao Chen <chenhao@biofourmis.com>
Subject: FW: Phi Med Europe: NerveCheck Quotation

Hi Chen Hao and Sandi,

This is the email from the company that makes this QST device: Thermal (heat/cold) and Vibration. I also have a quotation from them. They have 4 levels of heat/cold stimulus, and 9 levels for vibration. Please have a look at the documents and let me know your thoughts.

Stimulus	CPT (°C)	WPT (°C)
Null	32-35: silent Aδ and C nerve fibres	32-35 silent Aδ and C nerve fibres
Weak	25: Aδ and C nerve fibres	40: C nerve fibres
Medium	20: Aδ and C nerve fibres	43: C nerve fibres
Strong	15: C nerve fibres	46: C nerve fibres

Thanks
Chris

From: Chris Wilson Antuvan <chinnuchris@gmail.com>
Date: Thursday, 16 June 2022 at 9:08 AM
To: Chris Wilson <chris.wilson@biofourmis.com>
Subject: Fwd: Phi Med Europe: NerveCheck Quotation

CAUTION: This email has originated from outside of the organization! Please be cautious before you click on links, open attachments, and/or make payments or reply, and do so only if you recognise the sender's email address and know the content is safe!

----- Forwarded message -----

From: **Customer Service** <info@phimedeurope.com>
Date: Wed, Jun 15, 2022 at 10:47 PM
Subject: Phi Med Europe: NerveCheck Quotation
To: <chinnuchris@gmail.com>
Cc: Samantha Odriozola <samantha.odriozola@phimedeurope.com>

Dear Chris Wilson,

Thank you for contacting us and for your interest in NerveCheck applied in your research Objective Pain assessment model.

We wanted to bring you more information that could be relevant for your work together with NerveCheck. Thus, find below the explanation and information provided by Prof.Dr.Odriozola as well as the quotation for 1 NerveCheck and 1 pack of disposables (performing 110test each pack). No need for further calibration or maintenance.

For providing a more adjusted quotation, please let me know the number of patients you will need to test as well as the frequency and in how many places needs to be done the test, so I will know the number of disposables you should need to perform the study.

Do not hesitate to contact us for further information.
Thank you again and we look forward to hearing from you.

--



Customer Service

Sales & Marketing Dpt. | Phi Med Europe S.L.

w: phimedeurope.com

a: Passeig de Pere III, nº30 08242 Manresa, Barcelona, Spain

Technology awards



Member of



Skype: [phimedeurope2.0](https://www.skype.com/user/phimedeurope2.0) | LinkedIn: [Phi Med Europe S.L](https://www.linkedin.com/company/Phi-Med-Europe-S-L) | Facebook: [NerveCheck Master](https://www.facebook.com/NerveCheckMaster) | Twitter: [@PhiMedEurope](https://twitter.com/PhiMedEurope)

Confidentiality Note: This message is intended only for the use of the named recipient(s) and may contain confidential and/or privileged information. If you are not the intended recipient, please contact the sender and delete this message. Any unauthorised use of the information contained in this message is prohibited.